A Breakthrough Enzyme P24 Enhances Protein Bioavailability, Transforming Nutrition
LOS ANGELES, June 3, 2025 -- Amplifye, a biotechnology company specializing in enhancing protein nutrition through the development of proprietary enzymes, today announces the launch of its first consumer product, amplifyeP24. Without changing the amount of food you consume, amplifyeP24 can double protein absorption by breaking down proteins in the stomach into bioavailable peptides and free essential amino acids.
amplifyeP24 is a single capsule taken once a day with your largest meal, that acts on the protein in the food you're already consuming. It works on any protein source, whether meat, plant, or supplement-derived.
By doubling protein bioavailability, amplifyeP24 supports benefits such as deeper sleep, enhanced muscle recovery, digestive comfort, improved gut health, and sustained energy. Designed for diverse populations—from athletes pursuing peak performance to individuals with digestive challenges, or women in perimenopause trying to increase their protein consumption—amplifyeP24 bridges cutting-edge science with accessible health solutions.
"Protein is one of the most essential nutrients we consume, yet much of it goes unused by the body," said John Melo, Chief Executive Officer, amplifye. "amplifyeP24 unlocks the full potential of the protein you already consume, doubling absorption for measurable improvements in performance, recovery, and wellness. Backed by extensive research, third-party lab testing, and rigorous scientific development, this breakthrough in nutrition delivers noticeable results quickly."
Amplifye's proprietary enzyme, P24, leverages breakthrough science to enhance protein bioavailability. The company's precision enzyme platform optimizes human nutrition and transforms underutilized protein sources, creating new possibilities for sustainability across food, animal feed, aquaculture, and human health and wellness markets.
"We didn't just develop a product—we discovered a completely new enzyme with extraordinary properties," said Courtney McHugh, co-founder and Chief Commercial Officer, amplifye. "The enzyme is built on years of research in enzymology and was inspired by foundational principles recognized with the Nobel Prize in 2024. This discovery allows us to solve a long-standing protein digestion and bioavailability challenge."
Amplifye closed an $18.5M Series A funding round to accelerate the development and commercialization of its precision enzyme platform. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments and Astanor Ventures.
With the launch of amplifyeP24, Amplifye is poised to lead the charge in transforming the world's approach to protein nutrition. The company plans to expand its portfolio of enzyme-based solutions, continuing to leverage its proprietary platform to address diverse nutritional needs and drive innovation in health and sustainability.
amplifyeP24 is now available for purchase at http://www.amplifyeme.com.
About Amplifye
Our mission is to amplify the nutritional impact of food while contributing to a more sustainable future. Amplifye is a pioneering biotechnology company that applies computational enzyme discovery and the power of precision fermentation. Coupled with AI, we develop and scale novel, clinically proven digestive enzymes that elevate the nutritional value of what we already eat. Amplifye combines scientific, nutrition, and engineering expertise, with a deep understanding of consumer needs, to make protein healthier for all, with no compromise. For more information. Please visit: www.amplifyeme.com.
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.